Carregant...
NEW DRUG DEVELOPMENTS IN PSYCHOSIS: CHALLENGES, OPPORTUNITIES AND STRATEGIES
All currently approved drugs for schizophrenia work mainly by dopaminergic antagonism. While they are efficacious for psychotic symptoms, their efficacy is limited for negative symptoms and cognitive deficits which underlie the substantive disability in this illness. Recent insights into the biologi...
Guardat en:
| Publicat a: | Prog Neurobiol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5362348/ https://ncbi.nlm.nih.gov/pubmed/27519538 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pneurobio.2016.07.004 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|